Skip to main content
Clinical Trials/NCT02435758
NCT02435758
Completed
Not Applicable

Multicenter Study on Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery

Third Affiliated Hospital, Sun Yat-Sen University1 site in 1 country262 target enrollmentApril 2015
ConditionsRectal Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Cancer
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Enrollment
262
Locations
1
Primary Endpoint
Sexual function
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

TME (Total mesorectum excision) is the golden standard of radical resection for mid-low rectal cancer. However, the damage of pelvic autonomic nerve following with TME principle will lead to high incidence of urinary and sexual function disorder. PANP (pelvic autonomic nerve preservation) surgery played a role in decreasing incidence of urinary and sexual function disorder. However, 32%-44% patients still suffered from urinary and sexual function disorder when underwent open (O-PANP-TME) or laparoscopic PANP TME surgery (L-PANP-TME).

In the early stage of work, the investigators performed preservation of Denovilliers' fascia in L-PANP-TME to discuss the protection of urinary and sexual function of male mid-low rectal cancer patients. The results showed that preservation of Denovilliers' fascia in L-PANP-TME significantly decreased incidence of urinary and sexual function disorder. In order to further confirm the early work, the investigators design a multicenter randomized controlled clinical trial to compare differences in urinary and sexual function protection and long-term outcomes between preservation and excision of Denovilliers' fascia in L-PANP-TME.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
June 15, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Responsible Party
Principal Investigator
Principal Investigator

Hongbo Wei

Assistant to the Dean

Third Affiliated Hospital, Sun Yat-Sen University

Eligibility Criteria

Inclusion Criteria

  • Male, 20 \< age (years) \< 71, informed consent;
  • Pathological diagnosis of rectal adenocarcinoma;
  • Tumors from anal edge 6 \~ 12 cm (measured by rigid proctoscope);
  • Preoperative staging T1-4 (T1-2 for anterior rectal wall) N0-2M0 rectal cancer (AJCC- 7th);
  • R0 TME surgical results is expected;
  • Preoperative ECOG physical status score 0/1;
  • Preoperative ASA grade I \~ III;
  • Normal urinary function (Bladder residual urine\<100ml), normal erection function (IIEF-5\>21) and ejaculation function grading as I level.

Exclusion Criteria

  • Complicated with acute ileus, perforation or hemorrhage;
  • Tumors with extensive invasion of surrounding tissues, TME not applicable; Imaging examination in regional integration intumescent lymph nodes (maximum diameter 3 cm or higher);
  • With other malignant diseases or with other malignant disease within 5 years; With other diseases need surgery;
  • A history of abdominal and pelvic major operation;
  • People with severe mental illness, or cannot be evaluated due to cultural or psychological factors;
  • No sexual life;
  • Critical organ dysfunction, unbearable surgery;
  • Unstable angina, myocardial infarction, cerebral infarction or hemorrhage within 6 months;
  • Systemic corticosteroids or immunosuppressive medication history within 1 month;
  • Pre-existent true incontinence or severe stress urinary incontinence.

Outcomes

Primary Outcomes

Sexual function

Time Frame: 14 days

IIEF-5 (International questionnaire of erectile function-5) and Ejaculation function classification are used to assess sexual function

Urinary function

Time Frame: 14 days

Urodynamic study and IPSS (International prostate symptom score) are used to assess urinary function

Secondary Outcomes

  • 3-year recurrence pattern(36 months)
  • Mortality(30 days)
  • Morbidity(30 days)
  • Sexual function(12 months)
  • Urinary function(12 months)
  • 5-year recurrence pattern(60 months)
  • 3-year overall survival rate(36 months)
  • 3-year disease free survival rate(36 months)
  • 5-year disease free survival rate(60 months)
  • 5-year overall survival rate(60 months)

Study Sites (1)

Loading locations...

Similar Trials